Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
Phase 1
Completed
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- Drug: ABBV-8E12
- Registration Number
- NCT03413319
- Lead Sponsor
- AbbVie
- Brief Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
- Subject completed Study C2N-8E12-WW-104 (NCT02494024)
- Subject was not eligible to enroll in Study M15-562 (NCT02985879)
Read More
Exclusion Criteria
- Subject weighs less than 35 kg at screening
- Subject has any contraindication or inability to tolerate brain MRI
- Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ABBV-8E12 ABBV-8E12 ABBV-8E12 administered by intravenous (IV) infusion.
- Primary Outcome Measures
Name Time Method Adverse Events From first dose of study drug to 20 weeks after last dose of study drug (up to 2 years, 5 months) Adverse events and serious adverse events will be monitored throughout the dosing period and for approximately 20 weeks after the last dose.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
University of California, San /ID# 170113
🇺🇸La Jolla, California, United States
Texas Health Physicians Group /ID# 170112
🇺🇸Dallas, Texas, United States